drugset / Trial / NCT00099216

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

NCT00099216

Phase 3 Completed 708 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

Timeline

Start
2001-08
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivastigmine Small molecule 3 mg
Subject Rivastigmine Small molecule 12 mg

Indications